Major cable and broadcast news outlets seem to have largely ignored a Wall Street Journal report that Donald Trump Jr. stands to potentially benefit financially from a deal between BlinkRx and the government-run TrumpRx pharmaceutical program. Apparently, neither The New York Times or The Washington Post covered the Journal’s findings either.
  • pelespirit@sh.itjust.works
    32·
    5 days ago

    On September 30, President Donald Trump announced TrumpRx, a government-run platform scheduled to launch in 2026 that would funnel consumers to drug companies’ direct-sale websites — precisely the service BlinkRx announced it could help facilitate in August. Donald Trump Jr. joined the company’s board in February of this year, and also serves as a partner of the investment firm 1789 Capital, a “lead investor” in BlinkRx. According to the Wall Street Journal report, before the President’s TrumpRx reveal, a BlinkRx representative “told one drug company that BlinkRx could be involved with running the site on behalf of the Centers for Medicare and Medicaid Services.”